Scientific Precision
Modern solutions
for freedom of
movement
Regain your mobility at any age. Promovia combines
biotechnological purity with clinically proven Italian
excellence to restore synovial fluid structure.
biotechnological purity with clinically proven Italian
excellence to restore synovial fluid structure.
Go to Catalog
01
Fast Action
Pain relief starting from the very first injection. Rapidly restores joint comfort and function through high-purity linear HA.
02
Long-term Effect
Sustained results that last up to 12 months, providing a full year of active life and biochemical stability within the joint.
03
Total Safety
High purity profile with minimal risk of side effects. Biocompatible Italian-made formula certified by EU standards.
Promovia® is a premium hyaluronic acid from Italy, designed to restore freedom of movement.
Based on advanced biotechnology and years of European expertise, Promovia combines purity, safety, and clinically proven efficacy.
Every molecule of the product is manufactured in Italy in accordance with the highest quality standards to provide reliable joint support for osteoarthritis, pain, and reduced mobility.
Based on advanced biotechnology and years of European expertise, Promovia combines purity, safety, and clinically proven efficacy.
Every molecule of the product is manufactured in Italy in accordance with the highest quality standards to provide reliable joint support for osteoarthritis, pain, and reduced mobility.
Promovia® Product Range
Precision-engineered hyaluronic acid concentrations for specific therapeutic requirements
PROMOVIA 80 mg/4ml
Only 1 injection per course
Rapid effect in severe forms of osteoarthritis
Specifications:
1 single injection every 1–2 years
Clinical indications:
➔ Grade II–III osteoarthritis (knee, hip, and shoulder joints)
➔ Severe pain syndrome, pronounced stiffness, and limited mobility
➔ Decreased synovial fluid function following trauma or due to degenerative processes in the joint ➔ Insufficient efficacy of NSAID therapy and standard courses of low-concentration HA (hyaluronic acid)
➔ Preparation for joint replacement surgery (endoprosthetics)
➔ Rehabilitation period following joint surgery
Rapid effect in severe forms of osteoarthritis
Specifications:
- Active ingredient: Sodium hyaluronate
- Molecular weight: 1500 kDa
- Concentration: 2–2.2% (20–22 mg/ml)
- Active ingredient content: 80–88 mg/4 ml
- Packaging: 5 ml syringe
- Origin: Biofermentation
1 single injection every 1–2 years
Clinical indications:
➔ Grade II–III osteoarthritis (knee, hip, and shoulder joints)
➔ Severe pain syndrome, pronounced stiffness, and limited mobility
➔ Decreased synovial fluid function following trauma or due to degenerative processes in the joint ➔ Insufficient efficacy of NSAID therapy and standard courses of low-concentration HA (hyaluronic acid)
➔ Preparation for joint replacement surgery (endoprosthetics)
➔ Rehabilitation period following joint surgery
More products
PROMOVIA 60 mg/4 ml
Effect lasts up to 12 months
Restoration of synovial fluid properties in degenerative-dystrophic joint changes
Specifications:
1 injection with an effect lasting up to 12 months
Clinical indications:
➔ Symptomatic therapy for Grade II osteoarthritis (knee, hip, and shoulder joints)
➔ Decreased synovial fluid function following trauma or due to degenerative processes in the joint ➔ Patient reluctance to undergo systemic pharmacological treatment
➔ Suitable for initial/maintenance therapy in chronic osteoarthritis
Restoration of synovial fluid properties in degenerative-dystrophic joint changes
Specifications:
- Active ingredient: Sodium hyaluronate
- Molecular weight: 1500 kDa
- Concentration: 1.5% (15 mg/ml)
- Active ingredient content: 60 mg/4 ml
- Packaging: 4 ml syringe
- Origin: Biofermentation (free from animal protein impurities and toxins)
1 injection with an effect lasting up to 12 months
Clinical indications:
➔ Symptomatic therapy for Grade II osteoarthritis (knee, hip, and shoulder joints)
➔ Decreased synovial fluid function following trauma or due to degenerative processes in the joint ➔ Patient reluctance to undergo systemic pharmacological treatment
➔ Suitable for initial/maintenance therapy in chronic osteoarthritis
More products
PROMOVIA 40 mg/2 ml
Alternative to systemic NSAID therapy
Rapid effect in severe forms of osteoarthritis
Specifications:
- Active ingredient: Sodium hyaluronate
- Molecular weight: 1500 kDa
- Concentration: 2–2.2% (20–22 mg/ml)
- Active ingredient content: 44 mg/2 ml
- Packaging: 4 ml syringe
- Origin: Biofermentation (free from animal protein impurities and toxins)
Recommended course:
2–3 injections, one syringe each, at 7–10 day intervals
Clinical indications:
➔ Initial stage of osteoarthritis (Grade I–II)
➔ Mild to moderate pain, joint stiffness
➔ Recovery following joint trauma
➔ Prevention of osteoarthritis in athletes and young patients
More products
PROMOVIA 24 mg/2 ml
Recommended for increased physical exertion
Rapid effect in severe forms of osteoarthritis
Specifications:
4–5 injections, one syringe each, at 7–10 day intervals
Clinical indications:
➔ Early signs of osteoarthritis: intermittent pain and mild joint stiffness
➔ Prevention of joint diseases in cases of hereditary predisposition
➔ Joint protection during increased physical exertion (athletes, dancers, manual workers)
Rapid effect in severe forms of osteoarthritis
Specifications:
- Active ingredient: Sodium hyaluronate
- Molecular weight: 1500 kDa
- Concentration: 1.2% (12 mg/ml)
- Active ingredient content: 24 mg/2 ml
- Packaging: 3 ml syringe
- Origin: Biofermentation (free from animal protein impurities and toxins)
4–5 injections, one syringe each, at 7–10 day intervals
Clinical indications:
➔ Early signs of osteoarthritis: intermittent pain and mild joint stiffness
➔ Prevention of joint diseases in cases of hereditary predisposition
➔ Joint protection during increased physical exertion (athletes, dancers, manual workers)
More products
Linear Hyaluronic Acid
No side effects compared to cross-linked hyaluronic acid. Suitable for patients with a high degree of sensitivity. Low risk of inflammation and edema after injection.
Adaptability
Large selection of concentrations and dosages. Targeted action: considers the stage of the disease and the nature of the pain. Suitable for both initial therapy and maintenance courses.
Sustainable Therapeutic Effect
Effect lasts up to 12 months after the course of therapy. Predictable treatment outcome with long- lasting biological stability.
Optimal Molecular Weight
Excellent biocompatibility. High viscosity and lubricating properties. Rapid pain relief (often after the very first injection).
Advantages of Promovia®
Innovative biotechnology for clinical excellence and patient safety.
European Quality Standard
Manufactured in Italy according to GMP and ISO 13485 standards. Successfully passed the on-site inspection for compliance with global pharmaceutical requirements. Multi-stage purification and control system. Included in the standard of therapy for degenerative joint diseases in leading European clinics.
Mechanism of Action
Biochemical integration of Promovia® within the synovial environment for comprehensive joint restoration.
Viscoelastic Restore
Optimization of lubrication and cushioning
properties to reduce articular friction.
properties to reduce articular friction.
Pain Relief
Inhibition of inflammatory mediators and
reduction of nociceptor sensitivity.
reduction of nociceptor sensitivity.
Chondroprotection
Structural protection of joint cartilage through
metabolic activity support.
metabolic activity support.
Functional Mobility
Full restoration of motion amplitude and
improvement in weight-bearing tolerance.
improvement in weight-bearing tolerance.
Technical Specification:
Promovia® contains highly purified linear hyaluronic acid (1500 kDa), providing structural parity with healthy endogenous synovial fluid. It restores joint homeostasis through complex therapeutic integration into the extracellular matrix.
Technical Support &
Distribution
Distribution
Our medical division provides comprehensive consultation
regarding clinical protocols and institutional distribution.
regarding clinical protocols and institutional distribution.
Inquiry Email
Promovia®
Advanced biotechnology for synovial
health restoration. Produced in Italy.
health restoration. Produced in Italy.
Therapeutics
HA Catalog
Clinical Trials
Protocols
Enterprise
About Italy R&D
Manufacturing
Contact
Regulatory
ISO Certifications
Privacy Policy
Terms of Use
© 2025 Promovia Pharmaceuticals S.p.A.
Certified EU Medical Device
Italian Origin
SAVA PHARM Kft.
Hungary, 9200 Mosonmagyaróvár,
Tímár utca 2.
VAT: HU32984132
Hungary, 9200 Mosonmagyaróvár,
Tímár utca 2.
VAT: HU32984132
adress
Send the form and we'll be
in touch
in touch
Promovia®
Advanced biotechnology for synovial
health restoration. Produced in Italy.
health restoration. Produced in Italy.
©2026 Promovia Pharmaceuticals S.p.A.
Certified EU Medical Device
Italian Origin